Navigation Links
Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
Date:10/12/2009

NEW HAVEN, Conn., Oct. 12 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced today that it had hired the investment banking firm Merriman Curhan Ford & Co. to assist in evaluating its strategic alternatives. These alternatives include any combination of a restructuring of the Company and its debt and a sale of the Company or its assets. The Company may also consider financing options.

As previously reported, the Oncologic Drugs Advisory Committee (ODAC), which is the cancer drug advisory panel of the U.S. Food and Drug Administration (FDA), voted in favor of Vion completing a randomized study defining the efficacy and safety of the Company's lead oncology therapeutic Onrigin(TM) (laromustine) Injection prior to receiving regulatory approval from the FDA. Vion had presented data for Onrigin(TM) for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). As Vion would need to raise additional capital to finance a new randomized trial, the Company is evaluating its strategic alternatives. If Vion is unsuccessful in achieving a restructuring, sale, financing or any other strategic transaction or combination thereof, it may have to consider curtailing or ceasing operations or liquidating its assets.

About Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin(TM) (laromustine) Injection and Triapine®. The Company has submitted a New Drug Application to the FDA for Onrigin(TM) for remission induction treatment for patients sixty years of age or older with de novo poor-risk AML. The FDA's Oncologic Drug Advisory Committee has recommended to the FDA that a new randomized trial for Onrig
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Ceregene, Inc. today announced additional ... double-blind, randomized, controlled Phase 2b clinical study of ... designed to deliver the neurotrophic factor neurturin, for ... robust response to CERE-120 in Parkinson,s patients diagnosed ... those diagnosed 10 years or more (p<.005), as ...
(Date:5/20/2013)... , May 21, 2013 ... Assembly, where world,s health ministers gather to address the ... Mental and neurological disorders (MNDs) affect 700 million ... non-communicable disease (NCD) burden ,Do You Mind?, ... the role each can play to collectively address MNDs ...
(Date:5/20/2013)... May 20, 2013 The Board of ... companies include OMNIlife science®, Inc., Enztec, Ltd., and Praxim, ... Board.  Guy Mayer , an ... of the Board of Directors and David Johnson, an ... director. Before joining OSI as Board ...
Breaking Medicine Technology:Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders 2Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 2Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 3
... Medical Receives European CE Mark Approvals for Drug Eluting Balloon... -- HELMOND, The Netherlands, November 16, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
... The largest natural allograft available on the market today ... The Musculoskeletal Transplant Foundation (MTF), the nation,s leading provider of ... cm sized grafts of FlexHD®, their hydrated acellular dermal matrix, ...   These two new sizes are the largest ...
Cached Medicine Technology:Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 2Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 3Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 4Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 5Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 6Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 7Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device 8Largest Acellular Dermal Allografts for Abdominal Wall Repair Now Available From MTF 2
(Date:5/21/2013)... The National Resident Matching Program NRMP® ... its Board of Directors. Hal B. Jenson, M.D., ... of Medicine, has been named President. Maria C. ... of California San Diego, is the President-Designate, and Glenn ... Medical Center, is the Secretary-Treasurer. Kenneth B. Simons, ...
(Date:5/21/2013)... Dr. James C. Wittig, Chief of ... Sarcoma Division of the John Theurer Cancer Center at ... named one of the top 13 Orthopedic Oncologists in ... Wittig is one of approximately 125 surgeons in America ... by surveying thought leaders in the field of Oncology. ...
(Date:5/21/2013)... 21, 2013 Brunswick Laboratories, Inc. ... the development and standardization of validated analytical methods, ... Brunswick Laboratories and the USDA, as a First ... This decision comes after extensive review by an ... Harnly of the U.S. Department of Agriculture. , ...
(Date:5/21/2013)... According to the Center for Disease Control and ... year. Over 800,000 of these bites require medical attention, ... should be aware of the danger that dog bites pose ... and children may sustain more serious injuries than an adult. ... the ages of 5 and 9 are at the greatest ...
(Date:5/20/2013)... USA Book News announced Monday that "The ... won the top honor in its 2013 International Book ... multitude of international titles published from 2011-2013, "The Infinity ... both mainstream and new age audiences looking to improve ... , “The Infinity Zone” is a phenomenon ...
Breaking Medicine News(10 mins):Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 2Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 3Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 2Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 3Health News:AOAC International Approves ORAC as First Action Official Method 2Health News:Personal Injury Law Firm Announces New Informational Graphic Regarding Dog Bite Injuries 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3
... 19 PAREXEL International Corporation (Nasdaq: PRXL ) ... Monday, January 26, 2009 after the close of the stock ... at www.parexel.com and on the PR Newswire website ... live webcast at 10:00 a.m. ET on Tuesday, January 27, ...
... a free prostate cancer screening and educational information on Monday 1/19 ... providing Atlanta residents with information about prostate health, the Prostate Proactivity ... (RCOG) and NewsTalk 750 WSB. , ... Atlanta, GA ...
... A collection of hospitals in eight cities around the ... surgical checklist during major operations can lower the incidence of ... study was led by researchers from the Harvard School of ... and the results are published Online First on Wednesday, January ...
... Believe in Khanna LASIK and change (improve) vision especially if you ... ... 18, 2009 -- In honor of the Presidential Inauguration on Tuesday, ... free LASIK surgery to any US citizen named "Barack Hussein Obama". ...
... Takes only minutes when temperatures drop to cause permanent damage, ... -- When the weather outside is frigid, do you know ... minutes for exposed skin to become frostbitten if the temperature ... at 20 miles per hour or more," Dr. Taizoon Baxamusa, ...
... the HIMSS Analytics Database, 85 percent of hospitals in the contracting phase ... since November 2007, when CCHIT released its first acute care or inpatient ... ... data from the HIMSS Analytics Database, 85 percent of hospitals in the ...
Cached Medicine News:Health News:PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call 2Health News:Radiotherapy Clinics of Georgia and NewsTalk 750 WSB Team Up to Promote Prostate Proactivity 2Health News:Radiotherapy Clinics of Georgia and NewsTalk 750 WSB Team Up to Promote Prostate Proactivity 3Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 2Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 3Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 4Health News:LASIK Surgery for "Barack Hussein Obama" 2Health News:Hard, Cold Facts About Frostbite 2Health News:85 Percent of Hospitals Select CCHIT Certified Products 2Health News:85 Percent of Hospitals Select CCHIT Certified Products 3Health News:85 Percent of Hospitals Select CCHIT Certified Products 4Health News:85 Percent of Hospitals Select CCHIT Certified Products 5
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: